Pfizer loe brands. losses of exclusivity in 2025.

Pfizer loe brands. Many factors can influence early or later generic entry. Also find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical Nov 21, 2018 · The future of Pfizer’s $5bn Lyrica brand is in jeopardy Over the past few years, Pfizer has tried using aggressive strategies to extend its flagship brand Lyrica's lifecycle and protect it from generic competition. They are the result of our hard work and deep commitment to creating a healthier world. for Consumers: SUTENT U. patent expiries). Therapeutic Areas. Feb 9, 2024 · After that period concludes, the brand faces loss of exclusivity (LOE) and is bound to relinquish monopoly while getting ready for the entry of several lower-cost generic (Gx) alternatives. approval for Prevnar 20 in June. , it is estimated that between 60,000 and 160,000 older adults are hospitalized and between 6,000 and 10,000 die due to RSV infection1 ABRYSVO’s approval will help offer older adults protection in the anticipated RSV season this fall Pfizer Inc. Between 2014 and 2020, a combined total of $259 billion in worldwide pharmaceutical sales are at risk Jul 9, 2023 · Gep Loe Brands Lead (North America) at Pfizer Vera Wu is a Gep Loe Brands Lead (North America) at Pfizer based in New York City, New York. Jun 8, 2016 · After years of intensive and expensive brand building, when a drug hits the patent wall, its equity evaporates overnight. The story of bringing a medicine to life is no different than any other process of creation. Temilayo Okeowo, based in New York, New York, United States, is currently a Finance Lead Peri_loe_adhd Porfolio of Brands at Pfizer. The company is working to extend its patent exclusivity. Here are some strategies company are employing to manage the drop in revenue. Food and Drug Administration (FDA) of a supplemental New Drug Application for XTANDI® (enzalutamide), following FDA expedited development and review programs (Priority Review Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp speed. There comes a point in the life of Depending on the customs and laws of a specific country, Pfizer offers colleagues health and wellness programs that help them maintain and promote optimum health and wellness. The company is expecting an LOE wave with 6 names facing Jan 14, 2025 · Pfizer drugs expected to lose U. In 2024, Eliquis emerged as Pfizer’s top-performing asset, growing 10% year-on-year operationally to bring in $7. Elelyso is the first FDA-approved plant cell-based ERT for Gaucher disease. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources Pharma Brands - LOE Strategy and Marketing · Accomplished pharmaceutical marketing and sales leader with expertise in the strategic planning and promotion of late-lifecycle brands, specifically 5 days ago · Pfizer is finally closing on approval of its rare disease therapy tafamidis in the US, several years after it first reached the market in Europe. This product information is intended only for residents of the United States. Pfizer-BioNTech The Pfizer-BioNTech vaccine (brand name: Comirnaty) was granted full Food and Drug Administration (FDA) approval in August 2021 for people ages 16 and older. But as the 2020s unfold, a familiar threat is resurfacing with unprecedented intensity: the Loss of Exclusivity (LOE). The key approaches to preserving meaningful value well into the post-patent-loss future are outlined. Feb 21, 2023 · Today, big drugmakers are facing an even larger “patent cliff,” with more than $200 billion in annual revenue at risk through 2030. The disease’s story started a lot earlier. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. Analyse The foundation for successfully optimising an established brand lies in comprehensive brand analysis. Apr 29, 2025 · As some programs are still confidential, some candidates may not be identified in this list. But those companies also have the financial flexibility to strike mergers and acquisitions to Growth Strategy Pfizer has become one of the largest pharmaceutical companies in the world primarily as a result of aggressive mergers and acquisitions (M&A). This section is intended for healthcare professionals practicing in the United States. Instructions for Use GENOTROPIN - U. But this time around, many of the brand name drugs losing market exclusivity are biologic products, manufactured from living cells, rather than the chemical pills that previously dominated the ranks of pharma top-sellers. There are thirteen drug master Temilayo Okeowo, based in New York, New York, United States, is currently a Finance Lead Peri_loe_adhd Porfolio of Brands at Pfizer. Nov 9, 2016 · Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. Vera received a Bachelors of Electrical Engineering degree from University of Delaware and a Master of Business Administration ( MBA ) from The Wharton School , University of Pennsylvania. (ETR:PFE) with a description, list of executives, contact details and other key facts. Jun 24, 2025 · Though Pfizer expects a moderate negative impact on revenues from the loss of exclusivity (“LOE”) in 2025, the impact is expected to be significant in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. There are three patents protecting this drug and two Paragraph IV challenges. Through this evolution, we are enabling greater independence, focus and responsiveness for our Looking out over the next decade, some of the biggest drugs in the industry will tumble off the patent cliff, putting pharma giants in the hot seat as investors clamor for their next blockbuster. 7 billion in revenue, down 6% operationally, but exceeded EPS expectations with strong cost management. Our Pfizer products hold the cure. The study relied on four theories explaining organizational performance and how the loss of exclusivity (LOE) or patent expiration affects the performance of innovator pharmaceutical industries. The theories underpinning this study are Systems Theory, Prospect Theory of patent, Monopoly Pricing theory, and Porter's Five forces. S. Jan 14, 2025 · Looking at the period from 2025 to 2030, Pfizer is facing a significant loss of exclusivity (LOE) wave that will reduce revenues by about $17-18 billion between 2026 and 2028. V. The “patent cliff” remains a formidable challenge, as patent expiration opens the door for generic and biosimilar competition, which can erode revenue by as much as 90% within the first year for certain products. (NYSE: PFE Apr 23, 2025 · According to Pfizer's CEO Albert Bourla, speaking during a recent fireside chat with TD Cowen: We have $17 billion of LOE ("loss of exclusivity," i. A curated list of blockbuster drugs going off-patent and the market impact on generics, biosimilars, and licensing opportunities. Bourla said the Jun 20, 2024 · The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Pfizer’s acquisitions have been focused on two main strategies: expanding its capabilities and acquiring brands with strong revenues. Inflammation and Immunology. Jul 22, 2019 · The drug is Pfizer's main patent expiration through 2026, CEO Albert Bourla said early this year, and that gives the company years to build up the brand's successors. Dec 27, 2024 · The pharmaceutical industry is bracing for a transformative year as 2025 approaches, with 25 high-revenue drugs set to lose patent protection. Pfizer has created a Loss Of Exclusivity (LOE) Center of Excellence within the Established Products Business Unit to offer brand teams that are facing similar LOEs the expertise to successfully navigate brand patent expirations. 3 days ago · The five-step approach for established brands optimisation 1. The FDA has accepted two separate marketing Feb 16, 2021 · Loss of exclusivity (LOE) is a natural milestone in a drug’s lifecycle. Johnson & Johnson, Amgen, Regeneron, Novartis and other Big Pharma players are facing down sizable U. Access prescribing information on Pfizer prescription medications. Kellogg’s Corn Flakes had Programmed death-1 (PD-1) is a protein that belongs to the CD-28 family and is expressed on T cells, dendritic cells, natural killer cells, macrophages, and B cells PD-1 functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and may play an important role in tumor evasion from host immunity Sasanlimab is a humanized The loss of exclusivity for these ten blockbuster drugs will significantly reshape the pharmaceutical landscape in 2025. GLOBAL COMMERCIAL BUSINESSES Our operating structure reflects our ongoing journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to deliver value to patients and our shareholders. The generic ingredient in IBRANCE is palbociclib. for Consumers: www. com GENOTROPIN U. UC Narrative. Ibrance is a brand name of palbociclib, approved by the FDA in the following formulation (s): IBRANCE (palbociclib - capsule;oral) Manufacturer: PFIZER Approval date: February 3, 2015 Strength (s): 75MG [RLD], 100MG [RLD], 125MG [RLD] IBRANCE (palbociclib - tablet;oral) Manufacturer: PFIZER Approval date: November 1, 2019 Strength (s PROVERA® (medroxyprogesterone acetate) medication page for healthcare professionals to search for scientific information on Pfizer medications. When your patients and their caregivers have questions or feel overwhelmed, Pfizer Oncology Together provides dedicated staff and resources to support patients prescribed Pfizer Oncology medications and help them find some of the answers they’re looking for—when they need it most. Executives leaned into margin-boosting strategies, with a cost savings plan targeting $7. Below is an in-depth look at the drugs, their therapeutic areas, patent Apr 21, 2025 · Despite its historical underperformance and declining dividend growth trajectory, Pfizer's 7. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources for Healthcare professionals: Nov 16, 2023 · TOKYO and NEW YORK, November 16, 2023 – Astellas Pharma Inc. Feb 15, 2018 · Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon. Jul 11, 2018 · Can Pfizer (NYSE:PFE) Grow with Several Upcoming Revenue Headwinds? The key topic for Pfizer is whether the company will be able to grow revenue in the mid-single digits going into the early 2020s 3 days ago · In the first themed article in our Market Access focus month, Charles Joynson discusses the price decline seen with patent expiration and the launch of generics. Price Reductions and Discounts BioGraph 55 is focused on developing first-in-class antibody therapies that target B-cells in T-cell inflamed solid tumors. Jun 24, 2025 · Though Pfizer expects a moderate negative impact on revenues from the loss of exclusivity (“LOE”) in 2025, the impact is expected to be significant in the 2026-2030 period as several of its What are the Pfizer major drugs patent expiry dates? Some of the leading Pfizer drugs expected to lose patent protection include Eliquis (2026), Ibrance (2027), and Xtandi (2027). Aug 29, 2025 · However, Pfizer’s strategic response mitigated this impact, retaining a substantial portion of the market. (NYSE: PFE) today announced that the companies received an approval by the U. Mar 22, 2025 · The conversation highlighted the promising pipeline for next-generation obesity treatments. Jun 21, 2022 · Bristol Myers Squibb, Pfizer and Merck will face extreme patent cliff exposure later in this decade. Medical Information Page - patient information, ways to contact Pfizer Medical & other resources for Become the leading biopharmaceutical company in China Letter from Jean-Christophe Pointeau China President, Pfizer Global Biopharma Business Group Learn More Science Product Browse All Products Pfizer Inc: The world's largest research-based pharmaceutical company. For example, it won U. genotropin. Investors are growing wary about the period from 2025-2030, when many big brands will Sep 30, 2021 · Pfizer already has newer products ready to take the baton from some of the top-selling products facing LOE within the next several years. Apr 4, 2022 · The pharmaceutical industry is in the midst of a steady period of moderate growth, but financial pressure will build toward the middle part of the decade as many key blockbuster brands face loss of exclusivity (LOE). Nov 13, 2024 · From 2030 onward, however, Lilly, Gilead and Novo are much more likely to take a hit from LOEs, alongside companies like Regeneron and Biogen, the analysts pointed out. May 21, 2024 · Pfizer shares have lagged behind the pharma rally due to inflated expectations, one-time losses, write-offs, and the Seagen acquisition. Each year, many of the Lipitor, a cholesterol-lowering medication developed by Pfizer, became a cornerstone in the pharmaceutical industry, transforming how drugs were marketed and sold. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. CEO Bourla's strategic Dec 4, 2018 · With Pfizer's profits after Lyrica expected to drop, the company is launching four new brands to build up revenue that will offset the impending revenue loss. Vertex, GSK, Pfizer, Takeda The unrelenting churning of time means many things to many people. Oct 21, 2024 · In this blog, we explore Loss of Exclusivity, the concept of the pharmaceutical patent cliff and outline strategies for navigating this challenge. Focused and effective late lifecycle management can preserve meaningful value for the brand. These programs can include health and disability insurance, preventative health programs, medical screening, free or reduced-cost vaccinations, discounts on Pfizer products, and nutrition and fitness counseling. The window for launching new growth drivers to fill the expected revenue gap is narrowing. Jul 20, 2023 · OptimizeRx helps pharma brands facing LOE by 2025 unlock value through cost-efficient digital point-of-care marketing and targeted HCP engagement. 2 days ago · DrugPatentWatch ® Estimated Loss of Exclusivity (LOE) Date for VYNDAQEL * The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. These expirations mark significant milestones for both innovators and generics/biosimilar manufacturers, promising market disruptions and expanded access to critical therapies. Feb 3, 2015 · Generic Ibrance Availability Last updated on Oct 8, 2025. The company’s lead program is a novel bispecific antibody that depletes regulatory B-cells to remove local immunosuppression for clinically effective anti-tumor T-cell immunity. Jul 21, 2021 · After a drug's patent expires, the manufacturer must relinquish control of the drug formula, a transition called loss of exclusivity (LOE). Dec 29, 2021 · Lastly, Pfizer’s business includes 11 drugs facing loss of exclusivity by 2030, per Porges’ calculation. The big push for its eradication began 50 years ago, in 1967. Pfizer Inc: The world's largest research-based pharmaceutical company. This case study explores how Pfizer’s A detailed strategic analysis of the question: How does Loss of Exclusivity (LOE) impact pharmaceutical companies\' market strategies and financial performance? Loss of Exclusivity necessitates Strategic Planning, Operational Excellence, and innovation to mitigate revenue loss and adapt market strategies in the pharmaceutical industry. For pharma execs, it’s a constant reminder of the need for new launches to supplant old meds. METHODS: Price erosion trends both pre 5 days ago · Loss of exclusivity (LOE) is a natural milestone in a drug’s lifecycle. Aug 28, 2025 · Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration. Mar 21, 2025 · This week on "The Top Line," we explore the potential impacts of this year's sizable patent cliff on the pharma industry at large. Also find the prescribing information, announcements, resources, and channels to connect with Pfizer Medical SUTENT® (sunitinib malate) This product information is intended only for residents of the United States. Learn more about Karen Kallenbach Femino's experience and education, or contac… In this section find an overview of our Pfizer Products and search for information on our most popular Pfizer products. Besides BMS-shared Eliquis, the other most significant product is breast cancer therapy May 1, 2023 · Hoping to give blockbuster prostate cancer drug Xtandi one more boost before it falls off the patent cliff, Astellas and Pfizer shared new data showing the androgen receptor inhibitor works in an Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Our products are the results of 1500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription. Aug 5, 2025 · At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. 7 billion to Pfizer in 2023 as the drug continues to dominate the anticoagulants market with 72% of all new-to-brand prescriptions (NBRx). To facilitate comparison across periods, revenues and expenses associated with Meridian and Mylan-Japan are reported in Pfizer’s Upjohn Feb 1, 2024 · Pfizer set the plan in motion to match its cost base with its long-term revenue opportunities. How We Are Organized Our new operating structure represents the next steps in Pfi zer’s journey to further revitalize our innovative core, enhance the value of our consumer and off-patent established brands and maximize the use of our capital to deliver value to patients and our shareholders. As drugmakers respond to the COVID-19 pandemic by developing vaccines and therapeutics, many of them are losing patent protection on older—and once lucrative—medicines. . Read Feb 19, 2025 · Asset at risk: Prevnar (2026), Ibrance (2027), Xtandi (2027) and Eliquis (2028) Eliquis’ loss of exclusivity could be even more painful for Pfizer, the prospects of which William Blair called “bleak” in its report. Its marketing strategy not only established Lipitor as the best-selling drug globally but also illustrated the importance of innovative advertising in the competitive healthcare market. Medication Guide Pfizer Oncology Together™ provides financial assistance resources to help patients access their prescribed Oncology medicines. Our products result from 1500 scientists overseeing more than 500,000 GENOTROPIN® (somatropin) medication page for healthcare professionals to search for scientific information on Pfizer medications. Previously, Vera was a Board Member at Taipei America n School. Feb 10, 2025 · Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian. 3 billion in 2024, representing a 9% year-on-year increase in sales. Dec 2, 2022 · We go over the best faucet brands for your kitchen and bathroom to help you find the right faucet brand for you! May 21, 2024 · Eliquis (apixaban), a direct Factor Xa inhibitor, brought $6. Pfizer's LOE has been far above average in recent years and this trend is set to reverse as soon as next year. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements that target unmet Aug 24, 2025 · Pfizer's diversified pipeline and new product launches are driving operational growth. patents in coming years include Inlyta, Xeljanz, Eliquis, Ibrance and Xtandi, according to the company's most recent annual report. The bispecific antibody mediates killing through a unique mode of action and is highly OBJECTIVES: The financial impact of Loss of Exclusivity (LoE) on pharmaceutical companies can be significant and can vary depending on specific drug and market conditions. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition of IBRANCE ® (palbociclib) to current standard-of-care first Jan 10, 2025 · For pharmaceutical companies, managing the transition of high-value products post-LOE (loss of exclusivity) is critical to sustaining revenue streams and market share. Click here to read more about PFE stock and why it is rated as a Hold. The aim of this research was to characterize the impact of LoE and company mitigation strategies on list prices in 8 European Countries; mainly Europe-5 and Denmark, Sweden, and Norway. The company reported $13. MYLOTARG - U. Growth Strategy Pfizer has become one of the largest pharmaceutical companies in the world primarily as a result of aggressive mergers and acquisitions (M&A). Mar 19, 2025 · Company profile for Pfizer Inc. Pfizer Inc discovers, develops, manufactures, and markets leading prescription medicines for humans and animals and many of the world's best-known consumer brands. Now let's consider our question about whether the worst is over for Pfizer. Over the last few years, loss of exclusivity (LOE) has slashed the market share of the most well-known drugs in a matter of months. Temilayo Okeowo brings experience from previous roles at Pfizer. Through this evolution, we are enabling greater independence, focus and responsiveness for our commercial businesses. SUTENT - U. Feb 16, 2024 · With the loss of exclusivity for not just Opdivo, but also cancer medication Revlimid and Pfizer-partnered blood thinner Eliquis within the next few years, Bristol Myers Squibb is currently working to launch six new drugs, that together could contribute over $15 billion in sales. 4 billion. 19 hours ago · Pfizer alleges that Ozempic maker Novo Nordisk’s proposed acquisition of Metsera would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan N. Addressing Feb 2, 2024 · In his first earnings call as Bristol Myers Squibb’s CEO, Chris Boerner laid out his plan to quickly navigate the company through a period filled with patent cliffs and new government-man | In Mar 5, 2025 · BMS, Pfizer Brace for Eliquis LOE 2024 Sales: $13. Director LOE Brands - Consumer (Director) working at Pfizer. 3 billion YOY Change: 9% The blood thinner Eliquis—developed and commercialized through the powerhouse partnership between Bristol Myers Squibb and Pfizer— made $13. Kellogg’s Corn Flakes had “generic” competition within a month of its launch more than 100 years ago, and yet it’s still the dominant brand in its market. Aug 28, 2019 · Loss of exclusivity (LOE) is a natural milestone in a drug’s lifecycle. What are authorized generics? May 31, 2023 · FDA’s decision is based on the data from the pivotal Phase 3 clinical trial in approximately 37,000 participants Each year in the U. This drug has one hundred and sixty-nine patent family members in fifty-six countries. Pfizer's biggest brands are in trouble. 63% dividend yield is attractive, making it a compelling income stock candidate. The loss of exclusivity for these drugs will likely open the market for generics, impacting Pfizer’s overall sales revenue. Pfizer’s Marketing Strategies Post-Generic Entry Pfizer employed a multifaceted approach to protect Lipitor’s market share, combining pricing strategies, loyalty programs, and innovative marketing tactics. May 1, 2024 · Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life Sales of the treatment for transthyretin amyloidosis widely beat Wall Street forecasts in the first quarter. The Established Products Business Unit’s broad product portfolio, capabilities in reformulations and low cost manufacturing position it to become one of the world’s top pharmaceutical players in the post-LOE market place. With patents on multibillion-dollar therapies nearing expiry, pharma giants are once again bracing for revenue Mar 19, 2025 · With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that have taken the leap off the patent cliff. Jun 13, 2025 · The Patent Cliff Returns: Can Big Pharma Innovate Fast Enough to Stay on Top? For decades, blockbuster drugs have fueled the pharmaceutical industry’s golden age. May 19, 2009 · Pfizer has more than 380 established products including many familiar brands such as Norvasc, Zoloft and Zithromax. In this section find an overview of our Pfizer Products and search for information on our most popular Pfizer products. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (Mylan) for generic drugs in Japan (Mylan-Japan). 4 days ago · When do Ibrance patents expire, and when can generic versions of Ibrance launch? Ibrance is a drug marketed by Pfizer and is included in two NDAs. losses of exclusivity in 2025. 7 billion by 2027 and an R&D team that’s gotten May 20, 2025 · The three vaccines in the U. e. Dec 12, 2024 · IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy Pfizer Inc. Additionally, there are indications that Pfizer is open to mergers and acquisitions, particularly in light of anticipated losses in sales due to the expiration of patents on several key products. With generics and biosimilars flooding the market, brand-name manufacturers will see sharp revenue declines. Jan 24, 2025 · Read this article if you want to know what companies does Pfizer own, its ownership details, revenue, and other key information about the company. r2myrso fg03c md5r ep fyd fax hlok6yf qwea dbk 8z